During the past decade, Specialty Compounding conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Specialty Compounding" are "Age-Related Maculopathy" (2 trials), "Age-Related Maculopathies" (1 trials), "Eye Diseases" (1 trials), "Macular Degeneration" (1 trials) and "Retinal Degeneration" (1 trials). Many other conditions were trialed in "Specialty Compounding" in a lesser frequency.

Most popular intervention types in "Specialty Compounding" are "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials) and "RN6G" (2 trials). Other intervention names were less common.

The vast majority of trials in "Specialty Compounding" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Specialty Compounding". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Specialty Compounding, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Specialty Compounding, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Specialty Compounding has several departments that took part in Clinical trials: "Regions Hospital Pharmacy" - 2 trials